Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma (SPL) has signed a research partnership to develop Dendrimer Enhanced Product (DEP) nanoparticle formulations for an anti-infective drug
  • The agreement is with Tianjin Chase Sun Pharmaceutical, a leading Chinese pharmaceutical company focused on commercialising healthcare products
  • Starpharma’s DEP drug delivery platform comprises three drugs targeted towards patients with solid tumours
  • Under the partnership, Chase Sun will fund all activities and costs and, if it chooses to commercialise the products, it will initiate a licence agreement
  • Company shares are up a slight 1.94 per cent and are trading for $1.05

Starpharma (SPL) has signed a research partnership with Tianjin Chase Sun Pharmaceutical to develop Dendrimer Enhanced Product (DEP) nanoparticle formulations for an anti-infective drug.

Starpharma’s DEP drug delivery platform is made up of DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These products are targeted towards oncology patients with solid tumours.

Under this new partnership, Starpharma will initially develop DEP nanoparticle formulations for an anti-infective product for Chase Sun, which is aimed at enhancing its performance and expanding its therapeutic utility.

Chase Sun will fund all activities and costs associated with the further development of any DEP product. If Chase Sun decides it wants to commercialise the DEP products, the companies will enter a licence agreement.

Chase Sun is a leading Chinese pharmaceutical company, with a $3 billion market cap. It is focused on research and development and the commercialisation of healthcare products.

“Chase Sun is a rapidly growing and innovative company in an important global market. This agreement illustrates the broad applicability of the DEP platform and will further develop the commercial potential of DEP in the anti-infective space, a therapeutic area of growing interest and need,” Starpharma CEO Dr Jackie Fairley said.

In addition to the initial agreement, the partnership also provides for the potential to conduct further DEP programs.

Company shares are up a slight 1.94 per cent and are trading for $1.05 each at 12:51 pm AEST.

SPL by the numbers
More From The Market Herald
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.